Breaking news re Prostvac in mCRPC

Apparently, late yesterday, Barvarian Nordic announced that Prostvac has failed to show efficacy in the Phase III PROSPECT trial of the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). Click here for Barvarian Nordic’s media release.

4 Responses

  1. This truly is disappointing. ProstVac sounded to me like a much less inconvenient treatment than Provenge. I had been hoping the trial would succeed.

  2. I wonder what the thinking is now regarding why it failed?

  3. Mark:

    Perhaps a more relevant question (already raised by some experts) is: were the positive results of the Phase II trial from several years ago misleading for some definable reason?

  4. Related to that, I was wondering if the Phase II sample set included an identifiable subset of patients who are particularly responsive. I want to emphasize that though it failed to show efficacy, the trial was not a failure. They monitored the immune response very closely, and we stand to learn a great deal about the biochemistry of the immune response. This “failure” may be the harbinger of the next success. It is worth recalling that Prostvac is still being explored (as far as I know) as a therapy combined with ipilimumab, combined with docetaxel for mHSPC, for active surveillance, and for biochemical recurrence.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: